Carbetocin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Carbetocin
- Pharmacist Assessment Report
- Carbetocin: oxytocin receptor agonist (long-acting oxytocin analogue) → isotretinoin-like syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Carbetocin: oxytocin receptor agonist (long-acting oxytocin analogue) → isotretinoin-like syndrome
One-Sentence Summary
Carbetocin is a long-acting oxytocin analogue peptide that acts on the oxytocin receptor and is used to prevent postpartum haemorrhage due to uterine atony. The TxGNN model predicts it may be relevant to isotretinoin-like syndrome, but this is a model prediction only, with no clinical trials and no publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | isotretinoin-like syndrome |
| TxGNN Prediction Score | 0.9915 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data |
| Number of Listed Products | 4 (valid: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for carbetocin are not available in the data compiled for this report. What is known is that carbetocin is a peptide oxytocin analogue that targets the oxytocin receptor (OXTR), and its recognised clinical use is preventing postpartum haemorrhage after uterine atony. An intranasal formulation has also been under development for hyperphagia in Prader-Willi syndrome.
No mechanistic link between oxytocin-receptor signalling and isotretinoin-like syndrome can be established from the available data. The high score (0.9915) is a computational output of the TxGNN model and likely reflects similarity to other syndromic or congenital disorders rather than validated biology. Any rationale beyond this would be speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 35607 | Cinomac 100mcg Injection | vial of 1 ml Injection | Not recorded |
| 73959 | Ecbosure 100mcg Injection | vial of 1 Injection | Not recorded |
| 184721 | Riligol Injection | vial of 1 ml Injection | Not recorded |
| 34497 | Caritec Solution for Injection | vial of 1 ml Solution for Injection | Not recorded |
Safety Considerations
- Drug Interactions: The only recorded item is pharmacological, not a drug–drug interaction: carbetocin binds the oxytocin receptor (OXTR) as its target. No interacting drugs with a severity level are recorded.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No clinical trials or publications address isotretinoin-like syndrome, and no mechanistic link can be drawn from the available data, so the evidence level is L5.
To proceed, the following is needed:
- Mechanism-of-action data for carbetocin and a plausible biological link to isotretinoin-like syndrome
- Package insert warnings and contraindications from the Indian licence holders
- Preclinical or clinical studies that directly examine isotretinoin-like syndrome
- Assessment of route compatibility (carbetocin is currently available only as injectables in India)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.